EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
This study was conducted to describe the modulation of plasma epidermal growth factor receptor (EGFR) ligands in EGFR-positive metastatic colorectal cancer (mCRC) patients during treatment with cetuximab and irinotecan and to explore the clinical implication of plasma levels' variations as potential biomarkers of benefit. Plasma amphiregulin (AR), epidermal growth factor (EGF), transforming growth factor-α, and heparin binding-EGF were assessed by ELISA in 45 chemorefractory mCRC patients, treated with cetuximab and irinotecan. Plasma levels were measured before and 1 h after the first administration of cetuximab, before and 1 h after the second administration, and before the third and the fifth cycles. KRAS and BRAF mutational status were determined. EGFR ligands' levels were differently modulated according to tumor KRAS and BRAF mutational status. In KRAS wild-type patients (n = 34), AR and EGF early increased and higher increases were significantly associated with worse clinical outcome. By adopting a specific cut-off value, patients with higher levels of AR 1 h after the first administration had significantly worse response rate, progression free survival, and overall survival. This hypothesis-generating study shows that EGFR ligands are significantly modulated by cetuximab plus irinotecan according to KRAS and BRAF mutational status, and they warrant further investigation as pharmacodynamic markers of resistance to anti-EGFRs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, multiple ligands of EGFR can activate EGFR, such as epidermal growth factor (EGF), transforming growth factor alpha (TGF-α), heparin-binding-EGF (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and epiregulin (EREG) (Figure 2) [133,134].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [133]
In the citing paper
“The expression of EGFR ligands in primary tumours is potentially related to anti-EGFR therapy efficiency [65, 66].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [66]
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403
Self-citationJacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368
Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5814 · Cited by 236
Research works printed but not linked: 1
- Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417 · DOI · Paper page
Cited by
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
The pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Shaked, Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.57 · Cited by 140
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
“(85) Consistent with this, increased levels of circulating EGFR ligands in the plasma of patients at the time of radiologic progression on cetuximab and irinotecan, suggest their potential role as a mechanism of acquired resistance to treatment.(86) This”
Background
Metadata
- Authors
- Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., Faviana, P., Sensi, E., Lupi, C., Fontanini, G., Basolo, F., Di Paolo, A., Danesi, R., Falcone, A., & Bocci, G.
- Affiliations
- University of Pisa (IT)
- Corresponding author
- Bocci, Guido
- ORCID
- Venue
- Targeted Oncology
- Published
- 2013-07-03
- Volume
- 9
- Issue
- 3
- Pages
- 205-214
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- OpenAlex
- W1984952201
- Cited by
- 33
- References
- 23
- Citations by year
- 2024: 4 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 4 · 2017: 3 · 2016: 7 · 2015: 3 · 2014: 3
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Targeted Oncology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR ligands, pharmacodynamic biomarkers, metastatic colorectal cancer, cetuximab, irinotecan, amphiregulin, epidermal growth factor, transforming growth factor-alpha, heparin-binding EGF, KRAS mutation, BRAF mutation, anti-EGFR resistance, plasma biomarkers, progression-free survival, overall survival
- MeSH terms
- Cetuximab, Irinotecan, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Ligands, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Proto-Oncogene Proteins B-raf, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. https://app.cochat.ai/papers/10.1007/s11523-013-0284-7
- The paper
- Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., Faviana, P., Sensi, E., Lupi, C., Fontanini, G., Basolo, F., Di Paolo, A., Danesi, R., Falcone, A., & Bocci, G. (2014). EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology. https://doi.org/10.1007/s11523-013-0284-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.